AstraZeneca has been a driving force in cardiovascular medicine for more than 100 years and we will again be leading the science in cardio-renal-metabolic disease at the first major cardiology meeting of 2018.
Our activities during the meeting will showcase the breadth of our distinctive science, including landmark real-world evidence, with the aim of advancing clinical practice and ultimately improving CV outcomes for millions of people worldwide.
Follow us on Twitter @AstraZeneca and join the conversation #ACC18.
AstraZeneca’s approach to CVRM
Estimated 17.7 million
people die each year from cardiovascular disease (CVD)
adults estimated to live with diabetes
Approximately 200 million
people live with chronic kidney disease (CKD)
The impact of CVD can be both immediate and long-lasting, with those who survive a potentially deadly CV event having to make significant lifestyle changes to reduce their risk of a secondary event.
The situation can be further complicated, with people who develop CVD at increased risk of other related conditions, such as kidney disease and diabetes. This adds to the challenges of managing CVD for both the patient and physicians.
We are committed to solving this problem. We understand the complexity of CVD and its association with both renal and metabolic disease (known collectively as cardiovascular, renal and metabolic diseases). We are using this knowledge to redefine the way these diseases are understood and how patients are treated, with the aim of identifying additional approaches to permanently reduce CV risk.
 Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1-25.
 International Diabetes Federation. IDF Diabetes Atlas, Eighth Edition, 2017.
 Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Trans Am Clin Climatol Assoc. 2014; 125: 229-246.
Veeva code: Z4-9334
Date of next review: February 2020